 |
Title: Consumer protection
[...]
The juvenile incidence of type 1 diabetes has increased by 37% during the last decade according to the research of the CEO of the Juvenile Diabetes Research Foundation (JDRF). For instance, nowadays in Australia there are more than 140,000 people with this awful disease. At present it is one of the most frequent chronic illnesses in children, occurring more often than cancer, cystic fibrosis, multiple sclerosis and muscular dystrophy combined."
[...]
It is necessary to take about 6 insulin injections every day for people with type 1 diabetes all the life long in order to stay alive. Besides, these people must also test their blood glucose levels about four times every day (Gale, 2002, p.588-594). Type 1 diabetes cannot be prevented, not can it be managed by diet or other lifestyle choices alone. Type 1 diabetes ravages almost every organ in the body. Most of people who have type 1 diabetes for more than 20 years suffer from tragic health problems, such as: kidney failure, blindness, nerves damage, amputations and heart attack.
[...]
Type 1 diabetes is a lifelong disease that can strike anyone. As long as insulin permits a person to be alive, it does not cure diabetes nor can it prevent severe health problems. That is why it is vital to continue to support research to find a cure for diabetes, and to reduce the percentage of children who have this disease. The Juvenile Diabetes Research Foundation has given over $800,000 for medical research into type 1 diabetes having sold jelly babies (Gale, 2002, p.588-594). Jelly Baby Month is held in Australia every year to raise funds for children with type 1 diabetes (Gale, 2002, p.588-594).
[...]
A special attention and work is needed to reduce the risk of complications. In addition, given the associated higher risks of cardiovascular disease, lifestyle modifications must be implemented to control blood pressure and cholesterol by exercising more and having an appropriate diet. In such countries as UK with a general practitioner system, attention and care may be extended generally in the community, with hospital-based specialist input only in case of complications, difficult blood sugar control, or participation in research.
[...]
The European nicotinamide diabetes intervention trial (ENDIT) also found no difference in protection from diabetes when participants were assigned to either oral nicotinamide or placebo treatment. Many challenges remain in this field; in particular assays for pathogenic human T cells are not yet available. Such assays have the potential to provide surrogate markers to guide evaluation of immunotherapy; in the absence of such markers, the first result of trials nowadays is the preservation of insulin secretion, for example, measurement of C peptide secretion.
[...]
Order your case study paper at Essay-Paper.net today.
|
|
